Mark Prvulovic

Mark Prvulovic


Before joining The Motley Fool, Mark worked as a freelance financial writer covering a variety of markets. Now he spends most of his time researching promising biotech and cannabis stocks, but from time to time will write about whatever catches his interest no matter the industry.

Recent articles

Is Teladoc Health a Buy?

Wall Street is optimistic about Teladoc's prospects. Should investors feel the same?

Is Sanofi's Stock a Buy?

With new promising results for its diabetes drug, is Sanofi a good investment right now?

Is Cara Therapeutics a Buy?

What should investors think of this promising biotech stock and its pruritus drug candidate?

Is Livongo Health Stock a Buy?

Livongo might be up after beating expectations, but does that make this stock an automatic buy?

Is Amarin a Buy?

Prospects for Amarin's omega-3 drug seem strong, but does that make the stock a buy?